MicroScan Conventional Panels

Antimicrobial resistance detection to combat MDROs

As the foundation of MicroScan ID/AST products, conventional panels deliver gold-standard1 accuracy with the fewest clinically significant reporting limitations of leading automated systems. This reduces the need for repeat testing, providing timely results without reliance on historical data.

To determine which MicroScan panels best fit your needs, use our easy-to-navigate MicroScan Panel GuIDe. Simply choose the antibiotics that define your formulary, and our tool will produce the options that best fit your criteria. 

This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.

Direct MIC Testing to Support Your Laboratory’s Antimicrobial Stewardship

The MicroScan portfolio of ID/AST panels supports unique institutional and geographic needs with a broad menu of antibiotic configurations and choice of inoculum preparation methods. With continued emergence of antimicrobial resistance, our direct MIC testing methodology provides confidence for detecting subtle changes in susceptibility results.

  • Support a variety of formulary needs with current antimicrobials and dilutions 
  • Test both ID and AST in a single combo panel to optimize workflow
  • Select MIC-only panel formats to complement MALDI-TOF ID* testing protocols
  • Use ID-only panels for targeted testing needs
  • Use either Prompt or turbidity inoculation method for workflow flexibility
  • Rely on visual confirmation of biochemical and susceptibility results for added confidence in unusual results
  • Get integrated ESβL confirmation on most Gram-negative panels

Combat Carbapenem-resistant Enterobacteriaceae with a New MicroScan Panel

The emergence and spread of carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) is a significant clinical and public health concern. Infections caused by CP-CRE are generally found in patients with underlying health problems. Due to the widespread use of carbapenems as empirical therapy, the frequency of CRE infections is increasing.

Combat emerging resistance with the most clinically relevant panels of antibiotics and dilutions, including the introduction of meropenem/vaborbactam (MEV), effective in treatment of infections caused by select KPC (Klebsiella pneumoniae carbapenemase) producing CRE pathogens.

Reduce the need for offline testing with the new Neg MIC 56 Panel, which includes:

  • The latest agents with activity vs. select CRE organisms:
    • ceftazidime/avibactam
    • ceftolozane/tazobactam
    • meropenem/vaborbactam
  • Extended fluoroquinolone dilutions support evolving Enterobacteriaceae and P. aeruginosa breakpoints
  • Minocycline for an alternative to MDR (multidrug-resistant) Enterobacteriaceae and Acinetobacter
  • 30 antibiotic tests including all 3 carbapenems and ESβL confirmation

Use of MicroScan Dried Gram-Negative Panels for Antimicrobial Susceptibility Testing of Meropenem/vaborbactam with Enterobacteriaceae Isolates

White Paper Use of Gram-negative Panels for AST Testing of Meropenem/vaborbactam

Learn how the recently FDA-approved antimicrobial agent, meropenem/vaborbactam, targets Enterobacteriaceae with β-lactamases. Meropenem is combined with a fixed concentration of vaborbactam, designed to target Enterobacteriaceae with β-lactamases, including KPC. Download this white paper to evaluate the accuracy of meropenem/vaborbactam on a MicroScan Dried Gram-Negative MIC Panel.

Download white paper

Product Details

  • 20 panels per box
  • Room-temperature storage
  • 1-year stability from date of manufacture
Ciprofloxacin Poster - ECCMID 2018

Multicenter Evaluations of Antibiotic MIC Results Using MicroScan Panels

Managing multidrug-resistant species and changing FDA antibiotic testing requirements? You can put your trust in the proven performance of MicroScan panels. A series of multicenter studies showed good correlation of MicroScan and CLSI reference panels. Find out more by reviewing the results of the studies.

Explore now

Discover a Full Portfolio of Highly Accurate Microbiology Solutions

Antibiotic resistance calls for robust and accurate microbiology solutions. Equip your laboratory with the precision and flexibility you need to detect and combat this emerging threat. Find out how MicroScan microbiology solutions can help.

Flexibility and Reliability: MicroScan Gram-negative and Gram-positive Panels

Learn more about MicroScan’s enhanced testing menu for accurate bacterial identification and susceptibility testing.

Accuracy Matters: Delivering Better Patient Care

See how to produce automated ID/AST results without sacrificing accuracy.

Biotype Lookup Program

The Biotype Lookup Program allows you to generate biotype information supported by LabPro Information Manager and Data Management System. It accesses an expanded identification database designed to assist with the identification of organisms whose atypical biochemical tests cause their assigned frequency cutoff points to be exceeded. The program supports all current MicroScan identification databases. To begin your search, select a panel classification, identification level and identification database, then enter the biotype number to obtain the requested information.

LabPro V4.41 Biotype Lookup tool

LabPro V4.42 or greater Biotype Lookup tool

1Kalorama United States Market for In Vitro Diagnostic Tests, 2017, pg. 878.

MALDI Biotyper is the property of Bruker Daltonik GmbH.
Prompt is a registered trademark of 3M.
Available under special contract; contact your Beckman Coulter sales representative for additional information.
§MEV vs. Best Available Therapy (BAT): 64% vs. 33%: meropenem, imipenem, ertapenem, tigecycline, colistin, polymyxin B, amikacin, gentamicin, tobramycin and ceftazidime/avibactam. Lee, Y. “Meropenem -Vaborbactam (Vabomere™): Another Option for Carbapenem-Resistant Enterobacteriaceae.” P&T® Journal. 2019 Mar; 44(3): 110 -113. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385729. Accessed March 8, 2019.